BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
130 patients (estimated)
Sponsors
Juno Therapeutics, a Bristol-Myers Squibb Company
Tags
CAR T Cell, B-Cell Maturation Antigen (BCMA), GPRC5D
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1819
NCT Identifier
NCT06153251

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.